Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Diethyl Phthalate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28481489 | 1.00 | TSHR (0.78) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| Diethyl Phthalate SCHEMBL2697040 | 0.96 | TSHR (0.84) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| Diethyl Phthalate SCHEMBL28274022 | 0.96 | TSHR (0.84) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| Diethyl Phthalate SCHEMBL9132522 | 0.96 | TSHR (0.84) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| SCHEMBL29628800 | 0.96 | TSHR (0.84) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| Phthalic Acid SCHEMBL6234815 | 0.96 | TSHR (0.84) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| SCHEMBL50234 | 0.96 | TSHR (0.84) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| Phthalic Acid SCHEMBL9132525 | 0.96 | TSHR (0.84) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| Hydrochloric Acid SCHEMBL10634124 | 0.94 | TSHR (0.81) | TSHRALDH1A1HSD17B10CDC25BTDP1 | |
| SCHEMBL11868454 | 0.94 | TSHR (0.81) | TSHRALDH1A1HSD17B10CDC25BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11944707-B2 | Dual release dosage form capsule and methods, devices and systems for making same | Gel Cap Technologies, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230293579-A1 | CRYSTALLINE ZIRCONIUM PHOSPHATE FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, AND USE OF THE SAME | CJ TECH HOLDINGS PTE LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| EP-4181934-A1 | CRYSTALLINE ZIRCONIUM PHOSPHATE FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, AND USE OF THE SAME | CJ TECH HOLDINGS PTE LTD. (SG) | 2023-05-24 | — | — | EP | disclosed |
| EP-3651721-A1 | DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME | Gel Cap Technologies, LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20190307699-A1 | DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME | Gel Cap Technologies, LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-10376471-B2 | Dual release dosage form capsule and methods, devices and systems for making same | Gel Cap Technologies, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2019014273-A1 | DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME | Gel Cap Technologies, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190008781-A1 | DUAL RELEASE DOSAGE FORM CAPSULE AND METHODS, DEVICES AND SYSTEMS FOR MAKING SAME | Gel Cap Technologies, LLC (US) | 2019-01-10 | — | — | US | disclosed |
| US-9504640-B2 | Modified release formulations of a bupropion salt | VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L. (LU) | 2016-11-29 | — | — | US | disclosed |
| EP-2965753-A1 | OSMOTIC DEVICE CONTAINING AMANTADINE AND AN OSMOTIC SALT | OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT (HU) | 2016-01-13 | — | — | EP | disclosed |
| WO-2001049267-A1 | MULTI-TABLET OXYBUTYNIN SYSTEM FOR TREATING INCONTINENCE | OSMOTICA CORP. (VG) | 2001-07-12 | — | — | WO | disclosed |
| US-6248359-B1 | SUSTAINED RELEASE | LABORATORIOS PHOENIX U.S.A., INC. (AR) | 2001-06-19 | — | — | US | disclosed |
| US-6004582-A | FOR IMMEDIATE DELIVERY OF A FIRST ACTIVE AGENT FOLLOWED BY A MONITORED, CONTINUOUS, CONTROLLED AND/OR RETARDED DELIVERY OF A SECOND ACTIVE AGENT WHICH IS THE SAME OR DIFFERENT AS THE FIRST ACTIVE AGENT; TIME-RELEASE AGENTS | LABORATORIOS PHOENIX U.S.A, INC. (AR) | 1999-12-21 | — | — | US | disclosed |
| EP-0914098-A1 | MULTI-LAYERED OSMOTIC DEVICE | Laboratorios Phoenix U.S.A., Inc. (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998053802-A1 | MULTI-LAYERED OSMOTIC DEVICE | LABORATORIOS PHOENIX U.S.A., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| US-5650170-A | Dosage form for delivering drug at a controlled rate to the intestine and to the colon | ALZA CORPORATION (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0521074-B1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORP (US) | 1994-03-02 | — | — | EP | disclosed |
| US-5178866-A | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORPORATION (US) | 1993-01-12 | — | — | US | disclosed |
| EP-0521074-A1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE. | ALZA CORP (US) | 1993-01-07 | — | — | EP | disclosed |
| WO-1991014426-A1 | DOSAGE FORM FOR DELIVERING DRUG TO THE INTESTINE | ALZA CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |